Ocata Therapeutics, Inc. (now owned by Acucela) has announced positive results in four Asian patients who were treated with the company’s proprietary RPE stem cells. These new data support previously reported positive long-term safety and signs of visual improvement, as reported here in October 2014. The Korean study, published online in Stem Cell Reports, features [Read More]
News
That All May Read
The National Library Service for the Blind and Physically Handicapped (NLS) provides books and magazines in Braille and talking-book formats to half a million US citizens who can’t read standard print because of visual or physical disabilities. A patron may choose to receive books free through the mail or download them from NLS’s Braille and [Read More]
Phase 2 Stem Cell Trial To Be Initiated
Ocata Therapeutics, Inc. (now owned by Acucela) announced on March 31, 2015 that the company has completed dosing of its Phase 1/2 studies for dry age-related macular degeneration (AMD) and Stargardt’s Macular Degeneration (SMD). A total of 38 patients have been safely dosed. The 200,000 cell cohort, the highest level planned, was successfully completed, paving [Read More]
All About Eyeglasses
For something so important, most people know very little about their eyeglasses. What do those abbreviations and numbers on the prescription mean? Why do my friend and I have the same prescription numbers, when my vision is so much worse? What does 20/20 mean? If my best vision without glasses is 20/200, am I legally [Read More]
Encapsulated Cell Technology Could Replace Injections in Wet AMD Patients
Neurotech Pharmaceuticals, Inc. announced on March 30, 2015 that the FDA has approved a Phase 2 clinical study of NT-503 Encapsulated Cell Therapy (ECT) for the treatment of wet age-related macular degeneration (AMD). ECT is an intravitreal implant that is genetically engineered to produce the biologic anti-VEGF drug NT-503 for at least 2 years. ECT, therefore, acts like [Read More]